Antibody Information

General Information of This Antibody

Antibody ID	ANI0KNPXN
Antibody Name	scFv(F8) antibody
Antibody Type	Monoclonal antibody (mAb)
Antibody Subtype	Humanized IgG scFv
Antigen Name	T-cell surface glycoprotein CD8 alpha chain (CD8A); T-cell surface glycoprotein CD8 alpha chain (CD8A)	Antigen Info

Each Antibody-drug Conjugate Related to This Antibody

Full Information of The Activity Data of The ADC(s) Related to This Antibody

F8-TNF [Investigative]

ADC Info

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 86.70% (Day 21)	Moderate CD8 expression (CD8 ++)
Method Description	CT26 Cells were implanted subcutaneously (s.c.) in the right flank of the mice using 3x10⁶ cells per animal. Mice received three injections of either 1 g F8-TNF (WEHI-164 tumor-bearing mice) or 2.5 g (CT26 tumor-bearing mice) every 48 h starting on the day after vaccination.
In Vivo Model	CT26 CDX model
In Vitro Model	Colon carcinoma	CT26 cells		CVCL_7254

References

Ref 1	Antibody-based Delivery of TNF to the Tumor Neovasculature Potentiates the Therapeutic Activity of a Peptide Anticancer Vaccine. Clin Cancer Res. 2019 Jan 15;25(2):698-709. doi: 10.1158/1078-0432.CCR-18-1728. Epub 2018 Oct 16.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.